Treatment Patterns and Outcomes in Over 2200 Newly Diagnosed Multiple Myeloma Patients: Supporting Bortezomib-Lenalidomide-Dexamethasone as a Preferred Regimen in the Absence of Anti-CD38 Antibodies
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F25%3A73633347" target="_blank" >RIV/61989592:15110/25:73633347 - isvavai.cz</a>
Result on the web
<a href="https://www.sciencedirect.com/science/article/pii/S2152265025042697?via%3Dihub" target="_blank" >https://www.sciencedirect.com/science/article/pii/S2152265025042697?via%3Dihub</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.clml.2025.10.022" target="_blank" >10.1016/j.clml.2025.10.022</a>
Alternative languages
Result language
angličtina
Original language name
Treatment Patterns and Outcomes in Over 2200 Newly Diagnosed Multiple Myeloma Patients: Supporting Bortezomib-Lenalidomide-Dexamethasone as a Preferred Regimen in the Absence of Anti-CD38 Antibodies
Original language description
A 17-year real-world analysis of 2,281 transplant-ineligible newly diagnosed multiple myeloma patients treatedwith bortezomib-based triplets showed superior response, PFS and OS with VRD compared with VMP, CVDand VTD, despite higher toxicity. In frail or elderly subgroups, regimen differences diminished. VRD representsthe most effective option where anti-CD38 therapies are not accessible.Background: Multiple myeloma (MM) is a hematologic malignancy defined by clonal proliferation of plasma cells inthe bone marrow. The introduction of bortezomib, a proteasome inhibitor, has significantly improved outcomes in MM,becoming a cornerstone of therapy since its approvals for relapsed/refractory MM in 2003 and newly diagnosed MM(NDMM) in 2008. Bortezomib induces apoptosis in malignant plasma cells by disrupting protein degradation pathways.Rationale: Triplet regimens combining bortezomib with immunomodulatory drugs, alkylating agents, and corticosteroidshave shown high efficacy, especially in NDMM patients ineligible for autologous stem cell transplant (ASCT). However,clinical trials often underrepresent real-world populations, with 40% to 50% of MM patients not meeting eligibility criteria. Methods: To address this evidence gap, we performed a retrospective analysis of national real-world data fromthe Czech Republic, assessing 17 years of experience with bortezomib-based triplet regimens in transplant-ineligibleNDMM patients. Conclusions: This study provides critical insights into the long-term effectiveness and applicability
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2025
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Clinical Lymphoma Myeloma & Leukemia
ISSN
2152-2650
e-ISSN
2152-2669
Volume of the periodical
26
Issue of the periodical within the volume
4
Country of publishing house
US - UNITED STATES
Number of pages
13
Pages from-to
"e470"-"e482"
UT code for WoS article
001736055900001
EID of the result in the Scopus database
2-s2.0-105023889294